JPWO2022004816A1 - - Google Patents

Info

Publication number
JPWO2022004816A1
JPWO2022004816A1 JP2022534097A JP2022534097A JPWO2022004816A1 JP WO2022004816 A1 JPWO2022004816 A1 JP WO2022004816A1 JP 2022534097 A JP2022534097 A JP 2022534097A JP 2022534097 A JP2022534097 A JP 2022534097A JP WO2022004816 A1 JPWO2022004816 A1 JP WO2022004816A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534097A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022004816A1 publication Critical patent/JPWO2022004816A1/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022534097A 2020-06-30 2021-06-30 Pending JPWO2022004816A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020113456 2020-06-30
JP2020149878A JP6967308B1 (ja) 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
PCT/JP2021/024837 WO2022004816A1 (ja) 2020-06-30 2021-06-30 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Publications (1)

Publication Number Publication Date
JPWO2022004816A1 true JPWO2022004816A1 (https=) 2022-01-06

Family

ID=78509585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020149878A Active JP6967308B1 (ja) 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
JP2022534097A Pending JPWO2022004816A1 (https=) 2020-06-30 2021-06-30

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020149878A Active JP6967308B1 (ja) 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Country Status (5)

Country Link
US (1) US20230242870A1 (https=)
EP (1) EP4173629A4 (https=)
JP (2) JP6967308B1 (https=)
CN (1) CN115811981A (https=)
WO (1) WO2022004816A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
CN117679520A (zh) * 2022-09-09 2024-03-12 北京达尔文细胞生物科技有限公司 用于防治后遗症期面神经麻痹的药物组合物及其应用
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521793A (ja) * 2003-06-27 2007-08-09 エチコン、インコーポレイテッド 分娩後由来細胞類を使用する、神経組織の再生および修復
JP2008525492A (ja) * 2004-12-23 2008-07-17 エシコン・インコーポレイテッド 産褥由来細胞を用いた脳卒中および他の急性神経変性障害の治療
JP2012512910A (ja) * 2008-12-19 2012-06-07 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 傷害後の神経組織の再生および修復
US20120230941A1 (en) * 2007-04-13 2012-09-13 Sing George L Methods for treating nervous system injury and disease
JP2012522014A (ja) * 2009-03-26 2012-09-20 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー アルツハイマー病の療法としてのヒト臍帯組織細胞
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
JP2014507389A (ja) * 2010-12-17 2014-03-27 アントフロゲネシス コーポレーション 羊膜由来接着細胞を使用する脊髄損傷及び外傷性脳損傷の治療
JP2016540014A (ja) * 2013-12-12 2016-12-22 サムスン ライフ パブリック ウェルフェア ファウンデーション 幹細胞由来のエキソソームを有効成分に含む脳血管疾患治療用薬学的組成物
JP2017517505A (ja) * 2014-05-18 2017-06-29 チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
JP2018518534A (ja) * 2015-06-12 2018-07-12 ハドソン インスティチュート オブ メディカル リサーチＨｕｄｓｏｎ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 治療方法
WO2018211510A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
WO2019012334A2 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited METHODS OF ISOLATION AND USE OF CD39 STROMAL STEM CELLS
JP2019535691A (ja) * 2016-11-03 2019-12-12 エグゾステム バイオテック リミテッド 間葉系幹細胞集団、それらの生成物およびそれらの使用
JP2020093988A (ja) * 2018-12-11 2020-06-18 株式会社 バイオミメティクスシンパシーズ 腸溶性カプセル
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO2002098361A2 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration
CN104321426A (zh) * 2012-03-28 2015-01-28 石匠株式会社 永生化干细胞以及以其生成物为有效成分的药物组合物和药物制剂

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521793A (ja) * 2003-06-27 2007-08-09 エチコン、インコーポレイテッド 分娩後由来細胞類を使用する、神経組織の再生および修復
JP2008525492A (ja) * 2004-12-23 2008-07-17 エシコン・インコーポレイテッド 産褥由来細胞を用いた脳卒中および他の急性神経変性障害の治療
JP2008525489A (ja) * 2004-12-23 2008-07-17 エシコン・インコーポレイテッド 産褥由来細胞を用いたパーキンソン病および関連の障害の治療
US20120230941A1 (en) * 2007-04-13 2012-09-13 Sing George L Methods for treating nervous system injury and disease
JP2012512910A (ja) * 2008-12-19 2012-06-07 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 傷害後の神経組織の再生および修復
JP2012522014A (ja) * 2009-03-26 2012-09-20 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー アルツハイマー病の療法としてのヒト臍帯組織細胞
JP2014507389A (ja) * 2010-12-17 2014-03-27 アントフロゲネシス コーポレーション 羊膜由来接着細胞を使用する脊髄損傷及び外傷性脳損傷の治療
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
JP2016540014A (ja) * 2013-12-12 2016-12-22 サムスン ライフ パブリック ウェルフェア ファウンデーション 幹細胞由来のエキソソームを有効成分に含む脳血管疾患治療用薬学的組成物
JP2017517505A (ja) * 2014-05-18 2017-06-29 チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
JP2018518534A (ja) * 2015-06-12 2018-07-12 ハドソン インスティチュート オブ メディカル リサーチＨｕｄｓｏｎ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 治療方法
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
JP2019535691A (ja) * 2016-11-03 2019-12-12 エグゾステム バイオテック リミテッド 間葉系幹細胞集団、それらの生成物およびそれらの使用
WO2018211510A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
WO2019012334A2 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited METHODS OF ISOLATION AND USE OF CD39 STROMAL STEM CELLS
JP2020093988A (ja) * 2018-12-11 2020-06-18 株式会社 バイオミメティクスシンパシーズ 腸溶性カプセル
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Also Published As

Publication number Publication date
JP2022016722A (ja) 2022-01-24
US20230242870A1 (en) 2023-08-03
EP4173629A4 (en) 2024-08-21
CN115811981A (zh) 2023-03-17
EP4173629A1 (en) 2023-05-03
JP6967308B1 (ja) 2021-11-17
WO2022004816A1 (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JPWO2022004816A1 (https=)
BR112021017747A2 (https=)
JPWO2023054317A1 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
JPWO2022180911A1 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104